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Commentary
Chagas disease, sometimes referred to as 
American trypanosomiasis, is an infectious 
disease caused by the parasite Trypanosoma 
cruzi (T. cruzi) which affects ∼7 million people 
worldwide. The disease is endemic in Mexico, 
Central and South America—especially poor 
rural areas—where it kills more people than 
any other parasitic infection.1 As a result of 
migration to Europe from Latin America, 
Chagas disease has been seen with increasing 
frequency in European countries.2 Thus, 
diagnosis and management of disease and 
prevention of transmission are an emerging 
challenge for the National Health Service 
(NHS) and for the United Kingdom (UK) 
public health.
To date, Chagas disease has only rarely 
been reported in the UK but consideration 
of migration data and the known prevalence 
of the disease in endemic countries suggests 
that it is likely that this reflects considerable 
under-ascertainment.3 If the estimated preva-
lence of 1.3% among 95 500 Latin American 
(LA) residents in London is correct then at 
least 95% of prevalent cases remain undi-
agnosed.4 In London alone there may be 
more than 130 000 LAs if irregular migrants, 
second-generation LA migrants and LA 
migrants with citizenship in other European 
countries are included.5
In Latin America, the infection is mostly 
acquired via the classic vector-borne route of 
transmission when people come into contact 
with the faeces of infected triatomine bugs, 
also known as ‘kissing bugs’ or ‘assassin bugs’. 
In the UK and other non-endemic areas 
where the vector is not present, the risk of T. 
cruzi acquisition is via the less common routes 
of transmission, such as blood transfusion, 
organ transplantation and vertical transmis-
sion from infected mothers.1 Vertical trans-
mission occurs in an average of 4.7% of all 
affected pregnancies, but varies significantly 
depending on the maternal country of birth.6 
Infants born with congenital Chagas may 
have a severe and life-threatening disease, 
although most infections are asymptomatic in 
early life.7 Treatment efficacy rate in congen-
ital cases is very high and therefore, identi-
fication of these cases will have the benefit 
of avoiding further complications of the 
disease and also the benefit of preventing the 
transmission.8
A review and meta-analysis by Requena-
Méndez and colleagues9 reported a pooled 
prevalence of 6.5% in pregnant LA migrants 
living in Europe; heterogeneity among studies 
was high, and migrants from Bolivia had the 
highest prevalence of the disease. Though 
pregnant LA women living in the UK are likely 
to be demographically similar, the prevalence 
of Chagas in this population is not known, 
as no routine screening is performed and 
most children who are infected will follow an 
asymptomatic clinical course. Nevertheless, 
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Summary box
 ► Chagas disease—caused by infection with parasite 
Trypanosoma cruzi (T. cruzi)—is an emerging but 
still largely unrecognised parasitic disease in the 
United Kingdom (UK).
 ► The classic vector-borne route of transmission by 
infected triatomine bugs only occurs in the endemic 
areas of Latin America, but less common routes 
of transmission—organ transplantations, blood 
transfusions and vertical transmission—have been 
reported in Europe.
 ► The UK has implemented health policy measures to 
control the transmission, including the systematic 
screening of at-risk blood and organ donations.
 ► Determining the prevalence of T. cruzi infection in 
Latin American women living in London remains 
a key priority to inform evidence-based screening 
policy and practice.
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up to 30%–40% of vertically infected children will suffer 
cardiac, neurological and/or gastrointestinal disease, up 
to 5–15 years after infection.10 Heart failure, arrhythmia 
and cardiomyopathy are the most common cause of 
death in infected adults.11
Potential risk exposure is high. Latin Americans 
are the second fastest growing non-European migrant 
population in London.5 In 2015, there were officially 
more than 54 000 LA women of childbearing age living 
in London and more than 2350 live births from women 
born in Latin America.12 However, estimating the actual 
size of the pregnant LA population in London is not 
easy; the country of birth is not routinely documented in 
maternity notes and electronic records, and LA ethnicity 
is not recognised in the current UK ethnicity classifica-
tion or in the antenatal family origin questionnaire used 
for haemoglobinopathy screening. Additionally, preg-
nant LA women in London are likely to experience major 
barriers to accessing healthcare services, and there is very 
little information on their healthcare needs.13
The UK has developed and implemented health policy 
measures to control the transmission of T. cruzi infection, 
including the systematic screening of at-risk blood, for 
which the UK was the first country to implement,14 and 
organ donations.15 The Migrant Health Guide, launched 
by Public Health England (PHE) in 2010 as a resource 
for health professionals working with migrants, recom-
mends that high-risk women should be offered sero-
logical testing as part of their routine antenatal care.3 
However, it is estimated that 3000 women per year from 
the affected regions receive maternity care each year in 
England and <6% of these women were tested in 2016 
(Chiodini PL, Hospital for Tropical Diseases, personal 
communication). Thus, the majority of women who 
might be infected are missing out on the opportunity 
for diagnosis and if infected, receiving treatment after 
weaning. Furthermore, their infants are not being inves-
tigated for signs of infection. Despite the advice in the 
Migrant Health Guide, there is currently no routine 
targeted screening for diagnosis and treatment of verti-
cally infected neonates—an intervention that is recom-
mended by the WHO because of its high treatment 
efficacy.1 8 Screening programmes for LA migrants in 
antenatal care units and primary care centres in France, 
Germany, Italy, Switzerland and Spain have been shown 
to be cost-effective.16 17
The international emergence of Chagas disease in LA 
migrants to non-endemic regions of the world and the 
silent nature of most cases of vertical transmission have 
important public health implications for policy-makers 
and clinicians in the UK. The current PHE recommen-
dation is invisible and not systematically implemented 
at present. Screening of all at-risk LA women of child-
bearing age, not just those who are already pregnant, 
may be a more appropriate strategy,17 facilitating precon-
ception antiparasitic treatment which greatly reduces 
the risk of vertical transmission. A coherent, unified 
screening strategy to detect and treat congenital Chagas 
is required in the UK and other non-endemic countries18 
together with an appropriate epidemiological surveil-
lance system19 20 able to evaluate the coverage and the 
efficiency of the programme.
The PHE recommendation presumably arose from the 
reasonable assumption that screening in antenatal clinics 
should be organisationally considerably more straight-
forward as the structures for screening for a range of 
infectious and non-infectious conditions are already in 
place. Lack of an appetite for implementation suggests 
that a more nuanced approach may therefore be neces-
sary. Determining the prevalence and risk factors for T. 
cruzi infection in LA women living in London is a key 
priority for informing the design and implementation of 
the most cost-effective health interventions.
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